Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 TrialLaurent Servais, Frederick J. Schnell, Daniela Leone et al.|Nucleic Acid Therapeutics|2021Cited by 128
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophyDanilo Buonsenso, Marika Pane, Beatrice Berti et al.|Pediatric Pulmonology|2020Cited by 22
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational studyEugenio Mercuri, Marika Pane, Simona Lucibello et al.|Neuromuscular Disorders|2019Cited by 0